65 related articles for article (PubMed ID: 10075381)
1. Retraction Note: Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats.
Hegazy N; Rezq S; Fahmy A
Neurotherapeutics; 2023 Oct; 20(6):1895. PubMed ID: 37817048
[No Abstract] [Full Text] [Related]
2. G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication.
Orr-Burks N; Murray J; Todd KV; Bakre A; Tripp RA
J Virol; 2021 Apr; 95(9):. PubMed ID: 33536179
[TBL] [Abstract][Full Text] [Related]
3. Roles of the WHHL rabbit in translational research on hypercholesterolemia and cardiovascular diseases.
Kobayashi T; Ito T; Shiomi M
J Biomed Biotechnol; 2011; 2011():406473. PubMed ID: 21541231
[TBL] [Abstract][Full Text] [Related]
4. Vascular wall ACE is not required for atherogenesis in ApoE(-/-) mice.
Weiss D; Bernstein KE; Fuchs S; Adams J; Synetos A; Taylor WR
Atherosclerosis; 2010 Apr; 209(2):352-8. PubMed ID: 19880118
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.
Montecucco F; Pende A; Mach F
Mediators Inflamm; 2009; 2009():752406. PubMed ID: 19390623
[TBL] [Abstract][Full Text] [Related]
6. Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1.
Cheng SM; Yang SP; Ho LJ; Tsao TP; Chang DM; Lai JH
Br J Pharmacol; 2004 Jul; 142(6):933-42. PubMed ID: 15210574
[TBL] [Abstract][Full Text] [Related]
7. Modulating atherosclerosis through inhibition or blockade of angiotensin.
Rosenson RS
Clin Cardiol; 2003 Jul; 26(7):305-11. PubMed ID: 12862295
[TBL] [Abstract][Full Text] [Related]
8. Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.
Chobanian AV
Curr Hypertens Rep; 2002 Apr; 4(2):93-5. PubMed ID: 11884263
[No Abstract] [Full Text] [Related]
9. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Hope S; Brecher P; Chobanian AV
Am J Hypertens; 1999 Jan; 12(1 Pt 1):28-34. PubMed ID: 10075381
[TBL] [Abstract][Full Text] [Related]
11. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
12. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
13. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit.
Chobanian AV; Hope S; Brecher P
Hypertension; 1995 Jun; 25(6):1306-10. PubMed ID: 7768578
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
